幹細胞合作與授權協議（2010-2026）

幹細胞交易的權威基準

幹細胞領域的合作是由再生醫學和早期創新方法所驅動的，其合約結構反映了複雜的開發過程、轉化研究挑戰和新興的治療應用。

本報告對超過 570 項幹細胞相關合作及許可協議進行了全面系統的分析，清晰且基於證據地展示了整個市場夥伴關係的設計、談判和執行方式。

清楚了解市場標準

本報告對幹細胞領域的合約實際是如何建構的提供了精確的理解。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清楚洞察基於治療領域、研發階段和合作夥伴情況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 將整個研究密集且不斷發展的治療領域中的合作夥伴行為模式和重複性合約結構視覺化。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解幹細胞合作中價值、風險和控制權的分配至關重要。在早期研發轉化研究（基礎研究成果的臨床應用）等複雜領域，其重要性較為突出。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 再生醫學交易的結構化與基準分析
• 在清晰的市場環境下準備談判
• 評估許可和合作機會
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過570項幹細胞相關合作及授權協議
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及研發階段）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 用於幹細胞療法交易的可靠依證
• 本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為在幹細胞領域建立、談判和評估夥伴關係關係提供了可靠的、基於依證的資源。

目錄

執行摘要

第1章：引言

第2章：幹細胞交易趨勢

• 過去幾年幹細胞合作
• 幹細胞交易中最活躍的參與者
• 幹細胞合約：依合約類型
• 幹細胞收縮：依治療領域
• 幹細胞合約：依行業分類
• 幹細胞合約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要幹細胞合約

• 按合約價值排名的頂級幹細胞合約

第4章：幹細胞領域最活躍的締約方

• 幹細胞領域最活躍的合約方
• 幹細胞領域最活躍的簽約方的公司簡介

第5章 幹細胞合約目錄

• 幹細胞合約目錄

第6章 幹細胞合約：依技術類型分類

• 合約目錄
• 合約目錄：幹細胞合約依公司名稱分類（A-Z）
• 合約目錄：幹細胞合約（依合約類型分類）
• 合約目錄：按治療領域分類的幹細胞合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for stem cell dealmaking

Stem cell partnering is driven by regenerative medicine approaches and early-stage innovation, with deal structures reflecting complex development pathways, translational challenges, and emerging therapeutic applications.

This report provides a comprehensive and structured analysis of 570+ stem cell collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how stem cell deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by therapy type, development stage, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a research-intensive and evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within stem cell partnerships, particularly in areas involving early-stage development and translational complexity.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark regenerative medicine transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 570+ stem cell collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy type, and development stage)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for stem cell dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how stem cell partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in stem cell dealmaking

• 2.1. Introduction
• 2.2. Stem cell deals over the years
• 2.3. Most active stem cell dealmakers
• 2.4. Stem cell deals by deal type
• 2.5. Stem cell deals by therapy area
• 2.6. Stem cell deals by industry sector
• 2.7. Deal terms for stem cell deals
  • 2.7.1 Stem cell deals headline values
  • 2.7.2 Stem cell deal upfront payments
  • 2.7.3 Stem cell deal milestone payments
  • 2.7.4 Stem cell royalty rates

Chapter 3 - Leading stem cell deals

• 3.1. Introduction
• 3.2. Top stem cell deals by value

Chapter 4 - Most active stem cell dealmakers

• 4.1. Introduction
• 4.2. Most active stem cell dealmakers
• 4.3. Most active stem cell deals company profiles

Chapter 5 - Stem cell contracts dealmaking directory

• 5.1. Introduction
• 5.2. Stem cell contracts dealmaking directory

Chapter 6 - Stem cell dealmaking by technology type

• Deal directory
• Deal directory - Stem cell deals by company A-Z
• Deal directory - Stem cell deals by deal type
• Deal directory - Stem cell deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Stem cell deals since 2010
• Figure 2: Active stem cell dealmaking activity since 2010
• Figure 3: Stem cell deals by deal type since 2010
• Figure 4: Stem cell deals by therapy area since 2010
• Figure 5: Stem cell deals by industry sector since 2010
• Figure 6: Stem cell deals with a headline value
• Figure 7: Stem cell deals with an upfront value
• Figure 8: Stem cell deals with a milestone value
• Figure 9: Stem cell deals with a royalty rate value
• Figure 10: Top stem cell deals by value since 2010
• Figure 11: Most active stem cell dealmakers since 2010
• Figure 12: Stem cell deals by technology type since 2010